Drug repositioning is designed to discover new uses of known drugs, which is an important and efficient method of drug discovery. Researchers only use one certain type of Collaborative Filtering (CF) models for drug repositioning currently, like the neighborhood based approaches which are good at mining the local information contained in few strong drug-disease associations, or the latent factor based models which are effectively capture the global information shared by a majority of drug-disease associations. Few researchers have combined these two types of CF models to derive a hybrid model with the advantages of both of them. Besides, the cold start problem has always been a major challenge in the field of computational drug repositioning, which restricts the inference ability of relevant models. Inspired by the memory network, we propose the Hybrid Attentional Memory Network (HAMN) model, a deep architecture combines two classes of CF model in a nonlinear manner. Firstly, the memory unit and the attention mechanism are combined to generate the neighborhood contribution representation to capture the local structure of few strong drug-disease associations. Then a variant version of the autoencoder is used to extract the latent factor of drugs and diseases to capture the overall information shared by a majority of drug-disease associations. In that process, ancillary information of drugs and diseases can help to alleviate the cold start problem. Finally, in the prediction stage, the neighborhood contribution representation is combined with the drug latent factor and disease latent factor to produce the predicted value. Comprehensive experimental results on two real data sets show that our proposed HAMN model is superior to other comparison models according to the AUC, AUPR and HR indicators.
Boosting drug-disease association prediction for drug repositioning via dual-feature extraction and cross-dual-domain decoding
Institute of Computing Science and Technology, Guangzhou University（广州大学计算科学与技术学院）；School of Computer Science and Technology, Dalian University of Technology（大连理工大学计算机科学与技术学院）；Electronics and Communication Sciences Unit, Indian Statistical Institute（印度统计研究所电子与通信科学部）
Drug repositioning is an attractive cost-efficient strategy for the development of treatments for human diseases. Here, we propose an interpretable model that learns disease self-representations for drug repositioning. Our self-representation model represents each disease as a linear combination of a few other diseases. We enforce proximity in the learnt representations in a way to preserve the geometric structure of the human phenome network - a domain-specific knowledge that naturally adds relational inductive bias to the disease self-representations. We prove that our method is globally opt…
Computational drug repositioning aims to discover new therapeutic diseases for marketed drugs and has the advantages of low cost, short development cycle, and high controllability compared to traditional drug development. The matrix factorization model has become the cornerstone technique for computational drug repositioning due to its ease of implementation and excellent scalability. However, the matrix factorization model uses the inner product to represent the association between drugs and diseases, which is lacking in expressive ability. Moreover, the degree of similarity of drugs or disea…
BiBLDR: Bidirectional Behavior Learning for Drug Repositioning
School of Computer Science, Hunan First Normal University（湖南第一师范学院计算机科学学院）；School of Computer Science and Engineering, Central South University（中南大学计算机科学与工程学院）
Learning accurate drug representations is essential for task such as computational drug repositioning. A drug hierarchy is a valuable source that encodes knowledge of relations among drugs in a tree-like structure where drugs that act on the same organs, treat the same disease, or bind to the same biological target are grouped together. However, its utility in learning drug representations has not yet been explored, and currently described drug representations cannot place novel molecules in a drug hierarchy. Here, we develop a semi-supervised drug embedding that incorporates two sources of in…
Drug repositioning holds great promise because it can reduce the time and cost of new drug development. While drug repositioning can omit various R&D processes, confirming pharmacological effects on biomolecules is essential for application to new diseases. Biomedical explainability in a drug repositioning model can support appropriate insights in subsequent in-depth studies. However, the validity of the XAI methodology is still under debate, and the effectiveness of XAI in drug repositioning prediction applications remains unclear. In this study, we propose GraphIX, an explainable drug reposi…
Isfahan University of Technology（伊斯法罕理工大学）；Amirkabir University of Technology（阿米尔卡比尔理工大学）；Isfahan University of Medical Sciences（伊斯法罕医科大学）；Carleton University（卡尔顿大学）
Drug repositioning offers an effective solution to drug discovery, saving both time and resources by finding new indications for existing drugs. Typically, a drug takes effect via its protein targets in the cell. As a result, it is necessary for drug development studies to conduct an investigation into the interrelationships of drugs, protein targets, and diseases. Although previous studies have made a strong case for the effectiveness of integrative network-based methods for predicting these interrelationships, little progress has been achieved in this regard within drug repositioning researc…
Computational drug repositioning technology is an effective tool to accelerate drug development. Although this technique has been widely used and successful in recent decades, many existing models still suffer from multiple drawbacks such as the massive number of unvalidated drug-disease associations and the inner product. The limitations of these works are mainly due to the following two reasons: firstly, previous works used negative sampling techniques to treat unvalidated drug-disease associations as negative samples, which is invalid in real-world settings; secondly, the inner product cann…
The computational drug repositioning aims to discover new uses for marketed drugs, which can accelerate the drug development process and play an important role in the existing drug discovery system. However, the number of validated drug-disease associations is scarce compared to the number of drugs and diseases in the real world. Too few labeled samples will make the classification model unable to learn effective latent factors of drugs, resulting in poor generalization performance. In this work, we propose a multi-task self-supervised learning framework for computational drug repositioning. T…
A pharmacological effect of a drug on cells, organs and systems refers to the specific biochemical interaction produced by a drug substance, which is called its mechanism of action. Drug repositioning (or drug repurposing) is a fundamental problem for the identification of new opportunities for the use of already approved or failed drugs. In this paper, we present a method based on a multi-relation unsupervised graph embedding model that learns latent representations for drugs and diseases so that the distance between these representations reveals repositioning opportunities. Once representati…
IIIT - Delhi（德里印度理工学院）；Inria Saclay（法国国家信息与自动化研究所萨克雷分部）；Univ. Paris Saclay（巴黎萨克雷大学）
This work formulates antiviral repositioning as a matrix completion problem where the antiviral drugs are along the rows and the viruses along the columns. The input matrix is partially filled, with ones in positions where the antiviral has been known to be effective against a virus. The curated metadata for antivirals (chemical structure and pathways) and viruses (genomic structure and symptoms) is encoded into our matrix completion framework as graph Laplacian regularization. We then frame the resulting multiple graph regularized matrix completion problem as deep matrix factorization. This i…
Computational Approaches for Predicting Drug-Disease Associations: A Comprehensive Review
School of Computer Science and Technology, Xidian University（西安电子科技大学计算机科学与技术学院）；Institute of Fundamental and Frontier Sciences, University of Electronic Science and Technology of China（电子科技大学基础与前沿研究院）
Imperial College London（帝国理工学院）；Twitter（推特）；USI Lugano（卢加诺大学）
Recent research efforts have shown the possibility to discover anticancer drug-like molecules in food from their effect on protein-protein interaction networks, opening a potential pathway to disease-beating diet design. We formulate this task as a graph classification problem on which graph neural networks (GNNs) have achieved state-of-the-art results. However, GNNs are difficult to train on sparse low-dimensional features according to our empirical evidence. Here, we present graph augmented features, integrating graph structural information and raw node attributes with varying ratios, to eas…
Combination therapy has shown to improve therapeutic efficacy while reducing side effects. Importantly, it has become an indispensable strategy to overcome resistance in antibiotics, anti-microbials, and anti-cancer drugs. Facing enormous chemical space and unclear design principles for small-molecule combinations, the computational drug-combination design has not seen generative models to meet its potential to accelerate resistance-overcoming drug combination discovery. We have developed the first deep generative model for drug combination design, by jointly embedding graph-structured domain …
University of Cambridge（剑桥大学）；Mila – Québec Artificial Intelligence Institute（Mila-魁北克人工智能研究所）；HEC Montréal（蒙特利尔高等商学院）
Complex or co-existing diseases are commonly treated using drug combinations, which can lead to higher risk of adverse side effects. The detection of polypharmacy side effects is usually done in Phase IV clinical trials, but there are still plenty which remain undiscovered when the drugs are put on the market. Such accidents have been affecting an increasing proportion of the population (15% in the US now) and it is thus of high interest to be able to predict the potential side effects as early as possible. Systematic combinatorial screening of possible drug-drug interactions (DDI) is challeng…
BVSIMC: Bayesian Variable Selection-Guided Inductive Matrix Completion for Improved and Interpretable Drug Discovery
Department of Statistics University of South Carolina（统计学系南卡罗来纳大学）；Department of Biostatistics University of South Carolina（生物统计学系南卡罗来纳大学）；Department of Biostatistics University of Florida（生物统计学系佛罗里达大学）；Department of Surgery University of Florida（外科医学系佛罗里达大学）；Department of Statistics George Mason University（统计学系乔治·梅森大学）
A Heterogeneous Network-based Contrastive Learning Approach for Predicting Drug-Target Interaction
College of Informatics, Huazhong Agricultural University（华中农业大学信息学院）；School of Computing, Mathematics & Engineering, Charles Sturt University（查尔斯斯特大学计算、数学与工程学院）；Artificial Intelligence & Cyber Futures Institute, Charles Sturt University（查尔斯斯特大学人工智能与网络未来研究院）；Faculty of Engineering, University of Mines and Technology（矿业技术大学工程学院）；School of Mathematics and Computer Science, Xinyu University（新余学院数学与计算机学院）
University of California, Berkeley（加州大学伯克利分校）；Lawrence Berkeley National Laboratory（劳伦斯伯克利国家实验室）；Oak Ridge National Laboratory（橡树岭国家实验室）；University of Chicago（芝加哥大学）；Argonne National Laboratory（阿贡国家实验室）；Pacific Northwest National Laboratory（太平洋西北国家实验室）
We developed Distilled Graph Attention Policy Network (DGAPN), a reinforcement learning model to generate novel graph-structured chemical representations that optimize user-defined objectives by efficiently navigating a physically constrained domain. The framework is examined on the task of generating molecules that are designed to bind, noncovalently, to functional sites of SARS-CoV-2 proteins. We present a spatial Graph Attention (sGAT) mechanism that leverages self-attention over both node and edge attributes as well as encoding the spatial structure -- this capability is of considerable in…
